In our patient cohort, positive expression of CLDN18.2 was associated with PD-L1 positivity, and lower CLDN18.2 expression was observed in Borrmann type 3/4 tumours and moderately or highly differentiated tumours [20]. This evidence concerns the gene CLDN18 and neoplasm.